Monetary Management Group Inc. Purchases 30 Shares of Stryker Corporation $SYK

Monetary Management Group Inc. increased its position in shares of Stryker Corporation (NYSE:SYK) by 0.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,668 shares of the medical technology company’s stock after buying an additional 30 shares during the period. Stryker accounts for approximately 0.8% of Monetary Management Group Inc.’s holdings, making the stock its 29th biggest position. Monetary Management Group Inc.’s holdings in Stryker were worth $2,854,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Capital A Wealth Management LLC bought a new stake in Stryker during the fourth quarter valued at about $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker during the first quarter worth approximately $32,000. City Holding Co. boosted its position in shares of Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 74 shares during the period. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker in the first quarter worth $40,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Stryker in the fourth quarter worth $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $384.6550 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm has a fifty day moving average of $387.17 and a 200-day moving average of $379.49. The firm has a market capitalization of $147.06 billion, a price-to-earnings ratio of 50.95, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the prior year, the company earned $2.81 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by company insiders.

Analyst Ratings Changes

SYK has been the subject of a number of research reports. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Roth Mkm increased their target price on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. BTIG Research reissued a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 price target on Stryker and gave the company a “hold” rating in a report on Monday, August 4th. Finally, Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.